4 results on '"Paolo Chiodini"'
Search Results
2. A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24 163 patients
- Author
-
Dario Giugliano, Annalisa Capuano, Michela Petrizzo, Maria Ida Maiorino, Paolo Chiodini, Katherine Esposito, Giuseppe Bellastella, Domenico Cozzolino, Esposito, Katherine, Chiodini, Paolo, Maiorino, Mi, Capuano, Annalisa, Cozzolino, Domenico, Petrizzo, M, Bellastella, Giuseppe, and Giugliano, Dario
- Subjects
Blood Glucose ,medicine.medical_specialty ,Type 2 diabetes ,Saxagliptin ,Linagliptin ,Nomogram ,chemistry.chemical_compound ,Internal medicine ,medicine ,Humans ,Hypoglycemic Agents ,Vildagliptin ,Hemoglobin A, Glycosylated ,Glycated Hemoglobin ,Dipeptidyl-Peptidase IV Inhibitors ,Hypoglycemic Agent ,business.industry ,Medicine (all) ,Research ,General Medicine ,medicine.disease ,Algorithm ,Diabetes and Endocrinology ,Nomograms ,chemistry ,Diabetes Mellitus, Type 2 ,Meta-analysis ,Sitagliptin ,THERAPEUTICS ,Dipeptidyl-Peptidase IV Inhibitor ,business ,Alogliptin ,Algorithms ,Human ,medicine.drug - Abstract
Objectives: To develop a nomogram for estimating the glycated haemoglobin (HbA1c) response to different dipeptidyl peptidase-4 (DPP-4) inhibitors in type 2 diabetes. Design: A systematic review and meta-analysis of randomised controlled trials (RCTs) of DPP-4 inhibitors (vildagliptin, sitagliptin, saxagliptin, linagliptin and alogliptin) on HbA1c were conducted. Electronic searches were carried out up to December 2013. Trials were included if they were carried out on participants with type 2 diabetes, lasted at least 12 weeks, included at least 30 participants and had a final assessment of HbA1c. A random effect model was used to pool data. A nomogram was used to represent results of the metaregression model. Participants: Adults with type 2 diabetes. Interventions: Any DPP-4 inhibitor (vildagliptin, sitagliptin, saxagliptin, linagliptin or alogliptin). Outcome measures: The HbA1c response to each DPP-4 inhibitor within 1 year of therapy. Results: We screened 928 citations and reviewed 98 articles reporting 98 RCTs with 100 arms in 24 163 participants. There were 26 arms with vildagliptin, 37 with sitagliptin, 13 with saxagliptin, 13 with linagliptin and 11 with alogliptin. For all 100 arms, the mean baseline HbA1c value was 8.05% (64 mmol/mol); the decrease of HbA1c from baseline was -0.77% (95% CI -0.82 to -0.72%), with high heterogeneity (I2=96%). Multivariable metaregression model that included baseline HbA1c, type of DPP-4 inhibitor and fasting glucose explained 58% of variance between studies, with no significant interaction between them. Other factors, including age, previous diabetes drugs and duration of treatment added low predictive power (
- Published
- 2015
3. Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials
- Author
-
Katherine Esposito, Giuseppe Bellastella, Paolo Chiodini, Maria Ida Maiorino, Dario Giugliano, Annalisa Capuano, Esposito, Katherine, Chiodini, Paolo, Maiorino, Mi, Bellastella, Giuseppe, Capuano, Annalisa, and Giugliano, Dario
- Subjects
Adult ,Blood Glucose ,medicine.medical_specialty ,Time Factors ,MEDLINE ,Type 2 diabetes ,Saxagliptin ,Linagliptin ,chemistry.chemical_compound ,Internal medicine ,DPP-4 inhibitors ,Medicine ,Humans ,Hypoglycemic Agents ,Vildagliptin ,Randomized Controlled Trials as Topic ,Glycated Hemoglobin ,Dipeptidyl-Peptidase IV Inhibitors ,business.industry ,DIABETES & ENDOCRINOLOGY ,Research ,General Medicine ,medicine.disease ,Diabetes and Endocrinology ,Meta-analysis ,chemistry ,Diabetes Mellitus, Type 2 ,Sitagliptin ,business ,Alogliptin ,medicine.drug - Abstract
Objectives To evaluate glycaemic durability with dipeptidyl peptidase-4 (DPP-4) inhibitors in type 2 diabetes. Design A systematic review and meta-analysis of long-term randomised trials of DPP-4 inhibitors on haemoglobin A1c (HbA1c) was conducted. Electronic searches were carried out on the following databases: MEDLINE, EMBASE, Scopus and Web of Knowledge to December 2013. Searches were supplemented by a review of trial registries and references from identified trials. Trials were included if they lasted at least 76 weeks, and had intermediate and final assessments of HbA1c. Citations and full-text articles were screened by two reviewers. A random effect model was used to pool data. Participants Adults with type 2 diabetes. Interventions Any DPP-4 inhibitor (sitagliptin, vildagliptin, saxagliptin, linagliptin and alogliptin). Outcome measures The difference between final and intermediate HbA1c assessment was the primary outcome. Results We screened 461 citations and reviewed 12 articles reporting 12 trials in 14 829 participants. All trials were of 76 weeks duration at least. The difference in HbA1c changes between final and intermediate points averaged 0.22% (95% CI 0.15% to 0.29%), with high heterogeneity (I2=91%, p
- Published
- 2014
4. A journey into a Mediterranean diet and type 2 diabetes: a systematic review with meta-analyses
- Author
-
Paolo Chiodini, Dario Giugliano, Maria Ida Maiorino, Katherine Esposito, Giuseppe Bellastella, Demosthenes B. Panagiotakos, Esposito, Katherine, Maiorino, Maria Ida, Bellastella, Giuseppe, Chiodini, Paolo, Panagiotakos, Demosthene, and Giugliano, Dario
- Subjects
Adult ,Blood Glucose ,medicine.medical_specialty ,Mediterranean diet ,NUTRITION & DIETETICS ,Psychological intervention ,Type 2 diabetes ,Diet, Mediterranean ,PREVENTIVE MEDICINE ,Risk Factors ,Weight loss ,Internal medicine ,Diabetes mellitus ,Weight Loss ,Humans ,Medicine ,Diet, Fat-Restricted ,Randomized Controlled Trials as Topic ,Preventive healthcare ,DIABETES & ENDOCRINOLOGY ,business.industry ,Research ,Medicine (all) ,Cholesterol, HDL ,General Medicine ,Dietary pattern ,medicine.disease ,Diabetes and Endocrinology ,Endocrinology ,Diabetes Mellitus, Type 2 ,Cardiovascular Diseases ,medicine.symptom ,Metabolic syndrome ,business - Abstract
Objectives To summarise the evidence about the efficacy of a Mediterranean diet on the management of type 2 diabetes and prediabetic states. Design A systematic review of all meta-analyses and randomised controlled trials (RCTs) that compared the Mediterranean diet with a control diet on the treatment of type 2 diabetes and prediabetic states was conducted. Electronic searches were carried out up to January 2015. Trials were included for meta-analyses if they had a control group treated with another diet, if they were of sufficient duration (at least 6 months), and if they had at least 30 participants in each arm. A random-effect model was used to pool data. Participants Adults with or at risk for type 2 diabetes. Interventions Dietary patterns that described themselves as using a ‘Mediterranean’ dietary pattern. Outcome measures The outcomes were glycaemic control, cardiovascular risk factors and remission from the metabolic syndrome. Results From 2824 studies, 8 meta-analyses and 5 RCTs were eligible. A ‘de novo’ meta-analysis of 3 long-term (>6 months) RCTs of the Mediterranean diet and glycaemic control of diabetes favoured the Mediterranean diet as compared with lower fat diets. Another ‘de novo’ meta-analysis of two long-term RCTs showed a 49% increased probability of remission from the metabolic syndrome. 5 meta-analyses showed a favourable effect of the Mediterranean diet, as compared with other diets, on body weight, total cholesterol and high-density lipoprotein cholesterol. 2 meta-analyses demonstrated that higher adherence to the Mediterranean diet reduced the risk of future diabetes by 19–23%. Conclusions The Mediterranean diet was associated with better glycaemic control and cardiovascular risk factors than control diets, including a lower fat diet, suggesting that it is suitable for the overall management of type 2 diabetes.
- Published
- 2015
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.